Abstract
Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual's clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.
Original language | English (US) |
---|---|
Pages (from-to) | 1431-1438 |
Number of pages | 8 |
Journal | Journal of Alzheimer's Disease |
Volume | 84 |
Issue number | 4 |
DOIs | |
State | Published - 2021 |
Keywords
- Alzheimer's disease
- event-related potentials
- memantine
- neurocognition
- prepulse inhibition
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health